110 related articles for article (PubMed ID: 10794066)
1. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
Schroeder U; Schroeder H; Sabel BA
Life Sci; 2000; 66(6):495-502. PubMed ID: 10794066
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.
Schröder U; Sabel BA
Brain Res; 1996 Feb; 710(1-2):121-4. PubMed ID: 8963650
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier.
Schroeder U; Sommerfeld P; Sabel BA
Peptides; 1998; 19(4):777-80. PubMed ID: 9622035
[TBL] [Abstract][Full Text] [Related]
4. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles].
Aliautdin RN; Petrov VE; Ivanov AA; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 1996; 59(3):57-60. PubMed ID: 8974587
[TBL] [Abstract][Full Text] [Related]
5. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ
J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206
[TBL] [Abstract][Full Text] [Related]
6. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
Shamenkov DA; Petrov VE; Alyautdin RN
Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
[TBL] [Abstract][Full Text] [Related]
7. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).
Kreuter J; Alyautdin RN; Kharkevich DA; Ivanov AA
Brain Res; 1995 Mar; 674(1):171-4. PubMed ID: 7773690
[TBL] [Abstract][Full Text] [Related]
8. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
Das D; Lin S
J Pharm Sci; 2005 Jun; 94(6):1343-53. PubMed ID: 15858853
[TBL] [Abstract][Full Text] [Related]
9. Circadian phase-dependent antinociceptive reaction in mice determined by the hot-plate test and the tail-flick test after intravenous injection of dalargin-loaded nanoparticles.
Ramge P; Kreuter J; Lemmer B
Chronobiol Int; 1999 Nov; 16(6):767-77. PubMed ID: 10584177
[TBL] [Abstract][Full Text] [Related]
10. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
[TBL] [Abstract][Full Text] [Related]
11. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
[TBL] [Abstract][Full Text] [Related]
13. Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats.
Ambruosi A; Yamamoto H; Kreuter J
J Drug Target; 2005 Dec; 13(10):535-42. PubMed ID: 16390814
[TBL] [Abstract][Full Text] [Related]
14. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy.
Rousselle C; Clair P; Smirnova M; Kolesnikov Y; Pasternak GW; Gac-Breton S; Rees AR; Scherrmann JM; Temsamani J
J Pharmacol Exp Ther; 2003 Jul; 306(1):371-6. PubMed ID: 12682214
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
17. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
18. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.
Ambruosi A; Gelperina S; Khalansky A; Tanski S; Theisen A; Kreuter J
J Microencapsul; 2006 Aug; 23(5):582-92. PubMed ID: 16980278
[TBL] [Abstract][Full Text] [Related]
19. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.
Ambruosi A; Khalansky AS; Yamamoto H; Gelperina SE; Begley DJ; Kreuter J
J Drug Target; 2006 Feb; 14(2):97-105. PubMed ID: 16608736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
